Sage Therapeutics Stock Soars

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial instability. Learn more on SAGE stock here.
Biogen proposes acquisition of partner Sage Therapeutics
The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Sage Shares Surge Premarket After Biogen Proposes Takeover
Shares of Sage Therapeutics jumped nearly 40% in premarket trading Monday after the biopharmaceutical company received an unsolicited buyout bid from partner Biogen. Biogen, which already owns a roughly 10.
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline ...
BioPharma Dive4d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
FiercePharma5d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Nasdaq4d
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board ...
pharmaphorum4d
Biogen offers to buy out wilting Sage for $442 million
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...